Presseportal.de - Boehringer Ingelheim GmbHhttp://www.presseportal.de/pm/6631/boehringer-ingelheim-gmbh/rssPresseportal.de: Boehringer Ingelheim GmbH (Digitale Pressemappe)de-denews aktuell GmbHhttp://www.presseportal.de/images/logo_napresseportal.gifPresseportal.de - Boehringer Ingelheim GmbHhttp://www.presseportal.de/pm/6631/boehringer-ingelheim-gmbh/rssredaktion@presseportal.de (Jens Petersen)Sat, 11 Feb 2012 00:35:52 +0100Fri, 25 Mar 2011 18:56:06 +01006Boehringer Ingelheim vollzieht Akquisition der Amgen Fremont Produktionsstätte in den USABoehringer Ingelheim GmbH: Ingelheim, Deutschland (ots/PRNewswire) - Boehringer Ingelheim hat heute die Akquisition derbiopharmazeutischen Entwicklungs- und Produktionsstätte von Amgen in Fremont, Kalifornien (USA), formell abgeschlossen. Im Rahmen der Akquisition werden ...http://www.presseportal.de/pm/6631/2015084/boehringer-ingelheim-vollzieht-akquisition-der-amgen-fremont-produktionsstaette-in-den-usa/rssFri, 25 Mar 2011 18:56:06 +0100http://www.presseportal.de/pm/6631/2015084/boehringer-ingelheim-vollzieht-akquisition-der-amgen-fremont-produktionsstaette-in-den-usa/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Deutschland (ots/PRNewswire) - Boehringer Ingelheim hat heute die Akquisition derbiopharmazeutischen Entwicklungs- und Produktionsstätte von Amgen in Fremont, Kalifornien (USA), formell abgeschlossen. Im Rahmen der Akquisition werden ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesBoehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian CancerBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. ...http://www.presseportal.de/pm/6631/1532251/boehringer-ingelheim-initiates-first-phase-iii-clinical-trial-in-ovarian-cancer/rssThu, 17 Dec 2009 13:34:05 +0100http://www.presseportal.de/pm/6631/1532251/boehringer-ingelheim-initiates-first-phase-iii-clinical-trial-in-ovarian-cancer/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesFlibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)Boehringer Ingelheim GmbH: Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III ...http://www.presseportal.de/pm/6631/1512944/flibanserin-demonstrates-efficacy-and-tolerability-in-pivotal-phase-iii-trials-in-pre-menopausal/rssMon, 16 Nov 2009 14:18:47 +0100http://www.presseportal.de/pm/6631/1512944/flibanserin-demonstrates-efficacy-and-tolerability-in-pivotal-phase-iii-trials-in-pre-menopausal/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesHeinrich-Wieland-Preis 2009 für herausragende Leistungen in der Darstellung und Wirkung von Naturstoffen vergeben (mit Bild)Boehringer Ingelheim GmbH: Ingelheim, München (ots) - Professor Steven V. Ley von der University of Cambridge (UK) wurde heute mit dem diesjährigen Heinrich-Wieland-Preis für seine herausragenden Forschungsleistungen zur Synthese, Strukturanalyse und biologischen Wirkung von ...http://www.presseportal.de/pm/6631/1502202/heinrich-wieland-preis-2009-fuer-herausragende-leistungen-in-der-darstellung-und-wirkung-von/rssThu, 29 Oct 2009 14:00:05 +0100http://www.presseportal.de/pm/6631/1502202/heinrich-wieland-preis-2009-fuer-herausragende-leistungen-in-der-darstellung-und-wirkung-von/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, München (ots) - Professor Steven V. Ley von der University of Cambridge (UK) wurde heute mit dem diesjährigen Heinrich-Wieland-Preis für seine herausragenden Forschungsleistungen zur Synthese, Strukturanalyse und biologischen Wirkung von ... Lesen Sie hier weiter...
]]>Finanzenredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesBoehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's DiseaseBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the ...http://www.presseportal.de/pm/6631/1492932/boehringer-ingelheim-receives-approval-from-the-european-commission-for-mirapexin-r-sifrol-r/rssWed, 14 Oct 2009 09:08:45 +0200http://www.presseportal.de/pm/6631/1492932/boehringer-ingelheim-receives-approval-from-the-european-commission-for-mirapexin-r-sifrol-r/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesBoehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptinBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The ...http://www.presseportal.de/pm/6631/1483073/boehringer-ingelheim-s-diabetes-pipeline-continues-to-advance-as-the-company-announces-conclusion/rssMon, 28 Sep 2009 08:08:40 +0200http://www.presseportal.de/pm/6631/1483073/boehringer-ingelheim-s-diabetes-pipeline-continues-to-advance-as-the-company-announces-conclusion/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesBoehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR MutationsBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ ...http://www.presseportal.de/pm/6631/1450461/boehringer-ingelheim-to-commence-phase-iii-study-investigating-the-role-of-bibw-2992-tovok-tm-as/rssMon, 03 Aug 2009 07:04:52 +0200http://www.presseportal.de/pm/6631/1450461/boehringer-ingelheim-to-commence-phase-iii-study-investigating-the-role-of-bibw-2992-tovok-tm-as/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ ... Lesen Sie hier weiter...
]]>Finanzenredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesHead-to-Head Trial Demonstrates Viramune(R)'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanavir/ritonavirBoehringer Ingelheim GmbH: Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding ...http://www.presseportal.de/pm/6631/1443044/head-to-head-trial-demonstrates-viramune-r-s-similar-efficacy-and-superior-effect-on-lipid-profile/rssMon, 20 Jul 2009 09:06:55 +0200http://www.presseportal.de/pm/6631/1443044/head-to-head-trial-demonstrates-viramune-r-s-similar-efficacy-and-superior-effect-on-lipid-profile/rss Boehringer Ingelheim GmbH [Pressemappe]
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesEuropean Commission Approves Statement on Lipid Improvement for VIRAMUNE(R) LabelBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in ...http://www.presseportal.de/pm/6631/1435305/european-commission-approves-statement-on-lipid-improvement-for-viramune-r-label/rssMon, 06 Jul 2009 12:10:55 +0200http://www.presseportal.de/pm/6631/1435305/european-commission-approves-statement-on-lipid-improvement-for-viramune-r-label/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesBoehringer Ingelheim Receives Positive Recommendation From European Scientific Committee for a New Once Daily Mirapexin(R) (Pramipexole) Formulation for the Treatment Of Parkinson's DiseaseBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion ...http://www.presseportal.de/pm/6631/1429652/boehringer-ingelheim-receives-positive-recommendation-from-european-scientific-committee-for-a-new/rssFri, 26 Jun 2009 07:49:47 +0200http://www.presseportal.de/pm/6631/1429652/boehringer-ingelheim-receives-positive-recommendation-from-european-scientific-committee-for-a-new/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesNew Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy ResultsBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the ...http://www.presseportal.de/pm/6631/1418413/new-data-from-boehringer-ingelheim-s-ongoing-linagliptin-trial-programme-show-promising-safety-and/rssSat, 06 Jun 2009 17:06:35 +0200http://www.presseportal.de/pm/6631/1418413/new-data-from-boehringer-ingelheim-s-ongoing-linagliptin-trial-programme-show-promising-safety-and/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesBoehringer Ingelheim and the World Stroke Organization Announce Partnership in the World Stroke AcademyBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke ...http://www.presseportal.de/pm/6631/1412682/boehringer-ingelheim-and-the-world-stroke-organization-announce-partnership-in-the-world-stroke/rssWed, 27 May 2009 12:35:27 +0200http://www.presseportal.de/pm/6631/1412682/boehringer-ingelheim-and-the-world-stroke-organization-announce-partnership-in-the-world-stroke/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesOutcome of New Mirapexin(R)/Sifrol(R) (Pramipexole) Study set to Change Treatment of Depressive Symptoms in Parkinson's DiseaseBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare ...http://www.presseportal.de/pm/6631/1396597/outcome-of-new-mirapexin-r-sifrol-r-pramipexole-study-set-to-change-treatment-of-depressive/rssThu, 30 Apr 2009 08:12:40 +0200http://www.presseportal.de/pm/6631/1396597/outcome-of-new-mirapexin-r-sifrol-r-pramipexole-study-set-to-change-treatment-of-depressive/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesNew Study Results Support Once Daily, Prolonged Release Formulation of Mirapexin(R)/Sifrol(R) (Pramipexole) for the Treatment of Parkinson's DiseaseBoehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the ...http://www.presseportal.de/pm/6631/1395768/new-study-results-support-once-daily-prolonged-release-formulation-of-mirapexin-r-sifrol-r/rssWed, 29 Apr 2009 08:06:22 +0200http://www.presseportal.de/pm/6631/1395768/new-study-results-support-once-daily-prolonged-release-formulation-of-mirapexin-r-sifrol-r/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesNo Increased Risk of Treatment-Induced Augmentation in Restless Legs Syndrome (RLS) Demonstrated in Long-Term Placebo-Controlled Study With Mirapexin(R) / Sifrol(R) (Pramipexole)Boehringer Ingelheim GmbH: Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in ...http://www.presseportal.de/pm/6631/1394910/no-increased-risk-of-treatment-induced-augmentation-in-restless-legs-syndrome-rls-demonstrated-in/rssTue, 28 Apr 2009 08:05:00 +0200http://www.presseportal.de/pm/6631/1394910/no-increased-risk-of-treatment-induced-augmentation-in-restless-legs-syndrome-rls-demonstrated-in/rss Boehringer Ingelheim GmbH [Pressemappe]
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in ... Lesen Sie hier weiter...
]]>Finanzenredaktion@presseportal.de (Jens Petersen)Excelitas Technologies